Abstract 77P
Background
Neuroblastoma (NBL) is the most common and aggressive cancer in infants, and there are no robust predictive nomograms for NBL. In this study, a database from the Therapeutically Applicable Research to Generate Effective Treatments was applied to develop and validate a prognostic nomogram for the prediction of individual 5-year overall survival (OS) probability in patients with NBL.
Methods
A total of 729 eligible NBL patients with their clinicopathological factors and biological characteristics from the database were assigned to either the training cohort (n = 511) or the validation cohort (n = 218). Independent predictors were identified by fitting the Cox model with lasso penalty and then were assembled into a nomogram to predict survival. The model was developed for predicting individual 5-year OS probability and was then internally and externally validated, calibrated and compared in each cohort.
Results
Four independent prognostic factors (International NBL Staging System stage, ploidy, histology and Children’s Oncology Group risk group) were discriminated and achieved favourable prediction efficacy following the lasso model. The prognostic nomogram incorporated those factors that performed well in the training and validation cohorts with OS (HR = 0.36, 95% CI: 0.27-0.48, P < 0.0 001; HR = 0.54, 95% CI: 0.34-0.86, P = 0.0 086; respectively) and recurrence-free survival (HR = 0.52, 95% CI: 0.40-0.67, P < 0.0 001; HR = 0.66, 95% CI: 0.44-0.99, P = 0.044; respectively).
Conclusions
The robust prognostic nomogram with four independent prognostic factors can accurately and diversely predict OS and recurrence-free survival in NBL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract